Avanos Medical reveals shareholder lawsuits aiming to block the $25/share merger and supplements its proxy with fresh financial details

summarizeSummary

Avanos Medical faces two shareholder lawsuits seeking to block its $25/share acquisition, filed days before the July 22 vote. The company denies the claims but added new financial details to its proxy, including J.P. Morgan's valuation ranges that support the deal price.

check_boxKey Events · Legal and Risk Events · AVNS

• Shareholder Lawsuits Filed

  On June 29-30, 2026, two lawsuits—Williams v. Avanos and Stevens v. Avanos—were filed in New York Supreme Court, aiming to enjoin the $25/share merger over alleged proxy disclosure deficiencies. The company also received demand letters from other shareholders.

• Supplemental Proxy Disclosures

  Avanos voluntarily added new details to the Definitive Proxy Statement, including UBS's conflict disclosure (up to $5M fee), confirmation that AIP did not discuss executive employment terms pre-merger, and expanded J.P. Morgan fairness opinion analysis.

• J.P. Morgan Valuation Ranges

  The supplemental disclosures reveal J.P. Morgan's public trading multiples analysis implied equity value of $12.75–$23.50 per share, and precedent transactions analysis implied $9.75–$21.75 per share, both below the $25 merger consideration.

• Merger Vote Still on Track

  The special shareholder meeting remains scheduled for July 22, 2026. The board continues to unanimously recommend voting FOR the merger, and all regulatory approvals have been secured.

auto_awesomeAnalysis · AVNS · Industrial Applications And Services

Two shareholder lawsuits filed in late June seek to enjoin the $25 per share cash acquisition by American Industrial Partners, alleging disclosure deficiencies in the proxy. While Avanos denies the claims, it voluntarily supplemented the proxy with new details — including UBS's up to $5 million fee, the lack of pre-merger executive employment discussions, and expanded J.P. Morgan fairness opinion analysis showing implied equity values of $12.75–$23.50 from public trading multiples and $9.75–$21.75 from precedent transactions, both below the $25 offer. The lawsuits introduce uncertainty just days before the July 22 shareholder vote, though regulatory approvals are already secured. The supplemental disclosures strengthen the record but do not change the merger terms or board recommendation.